Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04510311 · ClinicalTrials.gov registry record · Early Phase 1
Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors
A Early Phase 1 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 32
- Enrollment target
NCT04510311: Completed Early Phase 1 study, sponsored by University of Michigan Rogel Cancer Center.
NCT04510311 is a Early Phase 1 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 32 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04510311, a Early Phase 1 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The goal of this exploratory study is to test whether \[18F\]3F-PHPG can be used reliably to map the locations of tumors in patients with neuroendocrine tumors. If so, the results of this study will be used to support further development of \[18F\]3F-PHPG as a clinical tool for neuroendocrine tumor localization and staging.
Primary Outcome
The maximum standardized uptake value (SUVmax) of \[18F\]3F-PHPG in neoplastic lesions will be quantified from the PET images using region-of-interest (ROI) analysis.
Interventions
- DRUG 3-[18F]Fluoro-para-hydroxyphenethylguanidine
- DRUG [123I] metaiodobenzylguanidine
- DIAGNOSTIC_TEST Positron emission tomography/computed tomography scan
- DIAGNOSTIC_TEST Planar scintigraphy scan
- DIAGNOSTIC_TEST Single photon emission computed tomography/computed tomography scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2020-10-19 |
| Est. Completion | 2024-12-31 |
| Phase | Early Phase 1 |
What the finished NCT04510311 record still lists
NCT04510311 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (40% lower).
The record links to 0 conditions, and to 5 interventions - of which 3-[18F]Fluoro-para-hydroxyphenethylguanidine is the first listed.
NCT04510311 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04510311 about?
NCT04510311 is a clinical study titled "Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors". The goal of this exploratory study is to test whether \[18F\]3F-PHPG can be used reliably to map the locations of tumors in patients with neuroendocrine tumors. If so, the results of this study will be used to support further development of \[18F\]3F-PHPG as a clinical tool for neuroendocrine tumor ...
What is the current status of trial NCT04510311?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 32 participants. The study started on 2020-10-19. Estimated completion is 2024-12-31.
What interventions are being tested in trial NCT04510311?
The interventions under investigation include: 3-[18F]Fluoro-para-hydroxyphenethylguanidine (DRUG), [123I] metaiodobenzylguanidine (DRUG), Positron emission tomography/computed tomography scan (DIAGNOSTIC_TEST), Planar scintigraphy scan (DIAGNOSTIC_TEST), Single photon emission computed tomography/computed tomography scan (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04510311?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04510311's enrollment target sits among peer trials
32 775th of 2000 higher than 1,207 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI